- Home
- KMDA vs MAZE Comparison
KMDA vs MAZE Comparison
Compare KMDA & MAZE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KMDA
- MAZE
- Stock Information
- Founded
- KMDA 1990
- MAZE 2018
- Country
- KMDA Israel
- MAZE United States
- Employees
- KMDA N/A
- MAZE N/A
- Industry
- KMDA Biotechnology: Pharmaceutical Preparations
- MAZE
- Sector
- KMDA Health Care
- MAZE
- Exchange
- KMDA Nasdaq
- MAZE NYSE
- Market Cap
- KMDA 399.7M
- MAZE 367.0M
- IPO Year
- KMDA N/A
- MAZE 2025
- Fundamental
- Price
- KMDA $7.74
- MAZE $11.86
- Analyst Decision
- KMDA Strong Buy
- MAZE Strong Buy
- Analyst Count
- KMDA 3
- MAZE 3
- Target Price
- KMDA $14.67
- MAZE $25.67
- AVG Volume (30 Days)
- KMDA 83.7K
- MAZE 100.7K
- Earning Date
- KMDA 08-13-2025
- MAZE 08-14-2025
- Dividend Yield
- KMDA 2.56%
- MAZE N/A
- EPS Growth
- KMDA 31.21
- MAZE N/A
- EPS
- KMDA 0.28
- MAZE 0.34
- Revenue
- KMDA $167,235,000.00
- MAZE $167,500,000.00
- Revenue This Year
- KMDA $14.51
- MAZE N/A
- Revenue Next Year
- KMDA $9.31
- MAZE N/A
- P/E Ratio
- KMDA $27.53
- MAZE $35.77
- Revenue Growth
- KMDA 11.83
- MAZE N/A
- 52 Week Low
- KMDA $4.93
- MAZE $6.71
- 52 Week High
- KMDA $9.16
- MAZE $17.00
- Technical
- Relative Strength Index (RSI)
- KMDA 66.78
- MAZE N/A
- Support Level
- KMDA $7.68
- MAZE N/A
- Resistance Level
- KMDA $7.86
- MAZE N/A
- Average True Range (ATR)
- KMDA 0.21
- MAZE 0.00
- MACD
- KMDA 0.05
- MAZE 0.00
- Stochastic Oscillator
- KMDA 67.61
- MAZE 0.00
About KMDA Kamada Ltd.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.
About MAZE MAZE THERAPEUTICS INC
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.